Ixekizumab
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD[1][2].
Product Specifications
CAS Number
1143503-69-8
Product Name Alternative
LY2439821
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ixekizumab.html
Purity
99.00
Solubility
H2O
Smiles
[Ixekizumab]
Molecular Weight
(146.44 kDa)
References & Citations
[1]Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. Published 2016 Apr 19.|[2]Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3) : results from two phase 3 randomised trials. Lancet. 2015;386 (9993) :541-551.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
IL-17
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC683450-100 1x 100 µL
Alpha Actinin 4 / ACTN4 (93), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
